Premium
Blood Glucose Control and Insulin Secretion Improved With Combined Therapy in Type 2 Diabetic Patients With Secondary Failure to Oral Hypoglycaemic Agents
Author(s) -
Iavicoli M.,
Cucinotta D.,
Mattia G.,
Lunetta M.,
Morsiani M.,
Pontiroli A. E.,
Pozza G.
Publication year - 1988
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.1988.tb01123.x
Subject(s) - medicine , insulin , endocrinology , diabetes mellitus , weight loss , type 2 diabetes , obesity
The influence of combined therapy using insulin and oral hypoglycaemic agents on blood glucose control and on insulin secretion in Type 2 diabetic patients with secondary failure to oral hypoglycaemic agents was evaluated. Type 2 diabetic patients ( n = 180) (98 normal‐weight, 82 over‐weight), at least 3 years from diagnosis, and having poor blood glucose control on oral hypoglycaemic agents for at least 3 months (fasting plasma glucose > 10.0 mmol l −1 ) despite intensive efforts at improvement, were included in the study. A single daily insulin injection (human ultralente), at a dose of 0.22 ± 0.07 U kg −1 d −1 in normal‐weight and 0.33 ± 0.10 U kg −1 d −1 in over‐weight patients, was added to the previous dietary and drug treatment for 6 months. A progressive and significant (2 p < 0.001) reduction of the mean daily blood glucose was observed during the first 3 months of combined therapy (from 13.2 ± 3.2 to 8.1 ± 2.1 mmol l −1 in normal‐weight and from 13.4 ± 3.1 to 8.8 ± 2.3 mmol l −1 in over‐weight patients), with no further significant changes thereafter. A significant increase (2 p < 0.001) in the mean daily C‐peptide concentration (from 0.50 ± 0.30 to 0.71 ± 0.29 nmol l −1 in normal‐weight and from 0.78 ± 0.36 to 1.00 ± 0.41 nmol l −1 in over‐weight patients) took place during combined therapy. No changes of body weight (+ 1.5 ± 1.2 kg in normal‐weight and +1.0 ± 1.0 kg in over‐weight patients) were observed.